Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROG 03.01: RT vs CRT for Esophageal Cancer Palliation
NCT00193882Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jul 2003
- Primary completion
- Mar 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) and fluorouracil in esophageal cancer (2 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Relief of dysphagia at 9 weeks. Started Jul 2003; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)fluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00193882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193882.